Simulations Plus Stock Intrinsic Value – Simulations Plus Reports $0.10 Non-GAAP EPS, $14.5M Revenue, Missing Expectations by $0.01 but Beating by $0.57M
January 5, 2024
🌧️Trending News
Simulations Plus ($NASDAQ:SLP), a software company that develops modeling and simulation products for the pharmaceutical, biotechnology, and medical device industries, recently reported their quarterly results. The company reported Non-GAAP EPS of $0.10 per share, missing the estimate by $0.01, but their revenue of $14.5M beat the forecast by $0.57M. Simulations Plus is a publicly traded company on the Nasdaq Global Market under the ticker symbol “SLP”. The company’s software products offer solutions in preclinical sciences, clinical trial data management, medical device simulation, and more.
Stock Price
Simulations Plus, a provider of software, consultancy services and proprietary drug-discovery and development, recently released their financial report for the quarter. The report reveals that they reported non-GAAP earnings per share of $0.10, beating expectations by $0.57M but missing expectations on earnings per share by $0.01.
Additionally, the company reported total revenues of $14.5M, missing expectations by $0.01M. Following the release of the financial report, SIMULATIONS PLUS stock opened at $44.8 and closed at $43.2, down by 3.4% from last closing price of 44.7. The stock experienced a decline in the past three months as investors reacted to the report’s performance. It remains to be seen if the stock can recover from this setback and move higher in the coming months. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Simulations Plus. More…
| Total Revenues | Net Income | Net Margin |
| 59.58 | 9.96 | 18.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Simulations Plus. More…
| Operations | Investing | Financing |
| 21.86 | 7.37 | -23.27 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Simulations Plus. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 186.1 | 16.07 | 8.53 |
Key Ratios Snapshot
Some of the financial key ratios for Simulations Plus are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 12.7% | -9.1% | 19.6% |
| FCF Margin | ROE | ROA |
| 29.5% | 4.3% | 3.9% |
Analysis – Simulations Plus Stock Intrinsic Value
GoodWhale recently conducted an analysis of SIMULATIONS PLUS‘s wellbeing. Our proprietary Valuation Line indicates that the fair value of SIMULATIONS PLUS’s share is around $55.4. However, the stock is currently being traded at $43.2 – which is undervalued by 22.1%. This discrepancy signals a potential buying opportunity for investors who are looking to invest in SIMULATIONS PLUS’s stocks. While no one can predict the future, our analysis suggests that SIMULATIONS PLUS is trading at a discount and might be an attractive option for investors. More…
Peers
The company was founded in 1986 and is headquartered in Lancaster, California. Simulations Plus Inc has three main competitors: Schrodinger Inc, Intercare DX Inc, and KDA Group Inc.
– Schrodinger Inc ($NASDAQ:SDGR)
Schrodinger Inc is a publicly traded company with a market capitalization of 1.52 billion as of 2022. The company has a return on equity of -15.16%. Schrodinger is a technology and software company that focuses on improving scientific discoveries through advanced computing. The company was founded in 1990 and is headquartered in New York City.
– Intercare DX Inc ($OTCPK:ICCO)
KDA Group Inc is a provider of engineering, construction and project management services. The company has a market cap of 14.81M as of 2022 and a Return on Equity of -120.56%. KDA Group Inc provides services to a range of industries including healthcare, education, commercial and institutional. The company has a strong focus on quality and safety and is committed to providing a high level of customer service.
Summary
Investing in Simulations Plus is a risky endeavor due to their recent earnings and revenue misses. The company reported a non-GAAP EPS of $0.10, missing the consensus estimate by $0.01 and revenue of $14.5M, beating the estimate by $0.57M. Despite this, the stock price moved down that same day, likely in part due to the earnings miss. Therefore, investors should weigh potential risks and rewards carefully before investing in Simulations Plus.
Related Posts
Recent Posts
